Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis
Status:
Completed
Trial end date:
2020-08-18
Target enrollment:
Participant gender:
Summary
The overall purpose of the study is to assess the efficacy of three different doses of BI
655064 against placebo as add-on therapy to standard of care (SOC) treatment for active lupus
nephritis in order to characterize the dose-response relationship within the therapeutic
range, and select the target dose for phase III development.